pharma · Metachromatic Leukodystrophy (MLD) · Late Metachromatic Leukodystrophy (MLD)
Shire
Shire is a pharma organization headquartered in CN. Primary therapeutic focus areas include Metachromatic Leukodystrophy (MLD), Late Metachromatic Leukodystrophy (MLD), Hunter Syndrome, Cytomegalovirus (CMV), Crohn's Dis
JP HQ
3,523 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Employees
- 3,523
- Programs
- 9
- Drugs
- 8
- Patents
- 0
rhASA
Phase 2 · small molecule · Late Metachromatic Leukodystrophy (MLD)
rhASA for Late Metachromatic Leukodystrophy (MLD) is a Phase 2 program (small_molecule) at Shire with 1 ClinicalTrials.gov record(s).
Internal code SHP611-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shire
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Late Metachromatic Leukodystrophy (MLD)
- Status
- active
- Trials
- 1